Lilly knocked back by FDA on Zyprexa for schizophrenia treatment
"We are disappointed by the FDA's decision and we are committed to ongoing discussions to better understand the agency's perspective regarding this recent case of excessive sedation and to define the path forward and the associated timeline"
Eli Lilly and Company has received a not approvable letter from the U.S. Food and Drug Administration for Zyprexa long-acting injection for the treatment and maintenance treatment of schizophrenia in adults, ... via News-Medical.Net